Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01604
|
|||||
| Drug Name |
Alpha-Zearalenol
|
|||||
| Synonyms |
alpha-Zearalenol; trans-Zearalenol; cis-Zearalenol; alpha zearalenol; UNII-59D4EVJ5KC; Zearalenol; 59D4EVJ5KC; CHEMBL371463; CHEBI:35065; A-ZEARALENOL; (3S,7R,11E)-7,14,16-trihydroxy-3-methyl-3,4,5,6,7,8,9,10-octahydro-1H-2-benzoxacyclotetradecin-1-one; .alpha.-Zearalenol; (-)-; A-Zearalenol; (2E,7R,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,14,16-tetraen-13-one; 36J; AC1NR4TQ; SCHEMBL343610; SCHEMBL109175; BIDD:ER0100; SGCUT00105; DTXSID8022402; FPQFYIAXQDXNOR-QDKLYSGJSA-N
|
|||||
| Indication | Cardiovascular disease [ICD11: BE2Z] | Preclinical | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H24O5
|
|||||
| Canonical SMILES |
CC1CCCC(CCCC=CC2=C(C(=CC(=C2)O)O)C(=O)O1)O
|
|||||
| InChI |
InChI=1S/C18H24O5/c1-12-6-5-9-14(19)8-4-2-3-7-13-10-15(20)11-16(21)17(13)18(22)23-12/h3,7,10-12,14,19-21H,2,4-6,8-9H2,1H3/b7-3+/t12-,14+/m0/s1
|
|||||
| InChIKey |
FPQFYIAXQDXNOR-QDKLYSGJSA-N
|
|||||
| CAS Number |
CAS 36455-71-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 320.4 | Topological Polar Surface Area | 87 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
4
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:35065
|
|||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (59D4EVJ5KC) | |||||
| 2 | ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites. Toxicol Lett. 2009 Oct 28;190(2):215-23. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.